The potential of223Ra and18F-fluoride imaging to predict bone lesion response to treatment with223Ra-dichloride in castration-resistant prostate cancer.
MetadataShow full item record
PURPOSE: The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of223Ra-dichloride, to assess the relationship between those doses and corresponding18F-fluoride uptake and to assess the potential of quantitative18F-fluoride imaging to predict response to treatment. METHODS: Five patients received two intravenous injections of223Ra-dichloride, 6 weeks apart, at 110 kBq/kg whole-body weight. The biodistribution of223Ra in metastatic lesions as a function of time after administration as well as associated lesion dosimetry were determined from serial223Ra scans. PET/CT imaging using18F-fluoride was performed prior to the first treatment (baseline), and at week 6 immediately before the second treatment and at week 12 after baseline. RESULTS: Absorbed doses to metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy. For individual patients, there was an average factor difference of 5.3 (range 2.5-11.0) between the maximum and minimum lesion dose. A relationship between lesion-absorbed doses and serial changes in18F-fluoride uptake was demonstrated (r2 = 0.52). A log-linear relationship was demonstrated (r2 = 0.77) between baseline measurements of18F-fluoride uptake prior to223Ra-dichloride therapy and changes in uptake 12 weeks after the first cycle of therapy. Correlations were also observed between both223Ra and18F-fluoride uptake in lesions (r = 0.75) as well as between223Ra absorbed dose and18F-fluoride uptake (r = 0.96). CONCLUSIONS: There is both inter-patient and intra-patient heterogeneity of absorbed dose estimates to metastatic lesions. A relationship between223Ra lesion absorbed dose and subsequent lesion response was observed. Analysis of this small group of patients suggests that baseline uptake of18F-fluoride in bone metastases is significantly correlated with corresponding uptake of223Ra, the associated223Ra absorbed dose and subsequent lesion response to treatment.
Version of record
License start date
Eur J Nucl Med Mol Imaging, 2017, 44 (11), pp. 1832 - 1844